Also Read: Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal For over 30 years, Congress has imposed price ceilings on prescription drugs ...

February 11, 2025 Novartis buys Blackstone's Anthos for up to $3.1 billion Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by ...

Novartis agreed to acquire Blackstone Life Sciences’ Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular-drug pipeline. The deal means the Swiss pharmaceutical company ...

Novartis has agreed to buy Anthos from private equity firm Blackstone for $3.1 billion, taking Factor XI inhibitor abelacimab back in-house.

U.S. FIRMS In addition to the CEOs of Qualcomm, FedEx, Standard Chartered, Citadel, Bain and KPMG, Pfizer CEO Albert Bourla, ...

February 11, 2025 Novartis buys Blackstone's Anthos for up to $3.1 billion Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by ...

Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2.

up for sale and is currently in talks with private equity giant Blackstone, JSW Paints, and Pidilite Industries. The non-binding offers are due by mid-March. In February last year, Novartis AG ...